The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's disease, the ...

The new test, from Fujirebio Diagnostics, Inc., identifies a sticky brain plaque, known as beta-amyloid, that is a key marker ...

The Lumipulse Alzheimer's blood test is the first of a new generation of tests that may replace brain scans and spinal taps to detect the disease.

The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...

Leqembi, produced by Eisai and Biogen, is not a cure for Alzheimer’s but significantly slows down cognitive decline. It ...

Leqembi market analysis highlights key dynamics, including growth potential driven by increased Alzheimer's prevalence, advancements in treatments, and innovations in IV dosing. Key player Eisai Co.

Campaigners have called for a change in the way treatments for dementia are assessed in the wake of the decision on the drug ...

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

The FDA has approved the first blood test for diagnosing Alzheimer’s disease, which could speed the path to treatment for ...

The FDA said it has issued its first official green light for a blood test to help diagnose Alzheimer’s disease, adding that ...

The U.S. Food and Drug Administration said on Friday it had cleared Fujirebio Diagnostics' blood test to diagnose Alzheimer's ...